Arcellx Inc (ACLX)
NASDAQ:ACLX
Want to see ACLX full AI Analyst Report?
ACLX Stock Chart & Stats
$115.05
-$3.36(-4.36%)
At close: 4:00 PM EST
$115.05
-$3.36(-4.36%)
Day’s Range― - ―
52-Week Range$47.86 - $115.13
Previous CloseN/A
Volume227.93K
Average Volume (3M)1.12M
Market Cap
$6.73B
Enterprise Value$6.74B
Total Cash (Recent Filing)$450.33M
Total Debt (Recent Filing)$96.26M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
May 07, 2026EPS Estimate
-1.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.00
Shares Outstanding58,479,813
10 Day Avg. Volume599,825
30 Day Avg. Volume1,119,312
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)9.12
Price to Sales (P/S)164.73
P/FCF Ratio-17.27
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue302.56
Enterprise Value/Gross Profit-466.86
Enterprise Value/Ebitda-34.06
Forecast
1Y Price Target
$112.85Price Target Upside-1.92% Downside
Rating ConsensusHold
Number of Analyst Covering16
EPS Forecast (FY)-3.71
Revenue Forecast (FY)$73.66M
Bulls Say, Bears Say
Bulls Say
Acquirer Strategic Fit And Launch CapabilityAnalyst notes Gilead's established CAR T manufacturing and commercial network should help maximize anito-cel's launch and expand patient access.
Clinical Differentiation And Safety ProfileAnalyst highlights anito-cel's D-domain binder and favorable safety signals that may reduce neurotoxicity compared with existing cell therapies, supporting stronger commercial adoption.
Regulatory ClarityAnalyst views regulatory acceptance of the biologics application with a standard review as providing a clear approval pathway and reducing regulatory uncertainty for the lead therapy.
Bears Say
Contingent Payment UncertaintyAnalyst warns the deal includes contingent payments tied to ambitious cumulative sales milestones, creating uncertainty about whether shareholders will realize the full transaction value.
Deal Execution And Contractual RiskAnalyst notes the absence of competing bids and a material adverse effect clause increase the likelihood the transaction proceeds as proposed while allowing the buyer to abandon the deal if the therapy encounters setbacks.
Valuation Cap And Limited UpsideAnalyst indicates the acquisition price aligns with the valuation model and effectively caps the stock, limiting upside potential for shareholders.
Arcellx Inc News
ACLX FAQ
What was Arcellx Inc’s price range in the past 12 months?
Arcellx Inc lowest stock price was $47.86 and its highest was $115.13 in the past 12 months.
What is Arcellx Inc’s market cap?
Arcellx Inc’s market cap is $6.73B.
When is Arcellx Inc’s upcoming earnings report date?
Arcellx Inc’s upcoming earnings report date is May 07, 2026 which is in 12 days.
How were Arcellx Inc’s earnings last quarter?
Arcellx Inc released its earnings results on Feb 26, 2026. The company reported -$1.003 earnings per share for the quarter, beating the consensus estimate of -$1.047 by $0.044.
Is Arcellx Inc overvalued?
According to Wall Street analysts Arcellx Inc’s price is currently Overvalued.
Does Arcellx Inc pay dividends?
Arcellx Inc does not currently pay dividends.
What is Arcellx Inc’s EPS estimate?
Arcellx Inc’s EPS estimate is -1.11.
How many shares outstanding does Arcellx Inc have?
Arcellx Inc has 58,479,813 shares outstanding.
What happened to Arcellx Inc’s price movement after its last earnings report?
Arcellx Inc reported an EPS of -$1.003 in its last earnings report, beating expectations of -$1.047. Following the earnings report the stock price went up 0.105%.
Which hedge fund is a major shareholder of Arcellx Inc?
Currently, no hedge funds are holding shares in ACLX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Arcellx Inc Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$112.85 (-1.92% Downside)
$112.85 (-1.92% Downside)
Blogger Sentiment
Bullish
ACLX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 4.6%
Last 30 Days ▼ 4.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
85.50%
12-Months-Change
Fundamentals
Return on Equity
-55.42%
Trailing 12-Months
Asset Growth
-15.09%
Trailing 12-Months
Company Description
Arcellx Inc
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
ACLX Stock 12 Month Forecast
Average Price Target
$112.85
▼(-1.92% Downside)
Technical Analysis
Protagonist Therapeutics
―
Apellis Pharmaceuticals
―
Immunovant
―
Beam Therapeutics
―
MoonLake Immunotherapeutics
―
Ownership Overview
Currently, No data available
---